Inhibition of glucagon hypersecretion from pancreatic α-cells is an appealing strategy for the treatment of 22 diabetes. Our hypothesis is that proteins that associate with glucagon within alpha cell secretory granules 23 will regulate glucagon secretion, and may provide druggable targets for controlling abnormal glucagon 24 secretion in diabetes. Recently, we identified a dynamic glucagon interactome within the secretory granules 25 of the α cell line, αTC1-6, and showed that select proteins within the interactome could modulate glucagon 26 secretion. In the present study, we show that one of these interactome proteins, the neuronal protein 27 stathmin-2, is expressed in aTC1-6 cells and in mouse pancreatic alpha cells, and is a novel regulator of 28 glucagon secretion. Stathmin-2 was co-secreted with glucagon in response to 55 mM K+, and 29 immunofluorescence confocal microscopy showed co-localization of stathmin-2 with glucagon and the 30 secretory granule markers chromogranin A and VAMP-2 in αTC1-6 cells. In mouse pancreatic islets, 31
Gene silencing experiments
was done based on a previously published protocol (26) and as we have done previously with some 120 modifications (21). Briefly, αTC1-6 cells were cultured in regular DMEM to 60% confluency. 121 Media were removed and replaced with 2 mL Opti-MEM (Cat# 31985-070, Gibco) containing 50 122 nM pooled siRNAs with Lipofectamine 2000. After 8h, media were changed to regular DMEM 123 without FBS and cultured for 72h. Then, media were refreshed and cells were cultured for 15 min 124 in the absence of presence of 55 mM KCl as described above. Gene silencing was confirmed by 125 analyzing mRNA expression levels of Stmn2. After removing media, cells were washed by cold 126 PBS (pH 7.4) and total RNA was extracted (RNeasy extraction kit; Cat # 74104, Qiagen). cDNA expression levels for stathmin-2 were normalized to that of β-Actin. The normalized level of 135 transcripts in the depleted cells was shown relative to that of the non-targeting negative control.
Relative expression levels were determined as percent of alterations compared to the control. Image Analysis: For cell image analysis, we prepared three coverslips for each group. Image used to calculate Pearson's correlation coefficient, as we described previously (27) (21).
191
For mouse pancreatic islets, images were captured using four channels of green (glucagon), red Stmn2 was knocked down (p<0.05) compared to the control ( Figure 4D ). These findings suggest 249 that Stmn2 plays a role in directing glucagon towards early endosomes.
Stmn2 overexpression increases glucagon presence in the late endosome/lysosome
251 compartment: Similar to our findings in early endosomes, there was a weak correlation between 252 glucagon and the late endosome-lysosome marker, Lamp2A (PCC = 0.2±0.02) in wild type αTC1-253 6 cells ( Figures 5A, D) . Following overexpression of Stmn2, the levels of colocalization between 254 glucagon and Lamp2A were significantly increased (PCC=0.89±0.05, p<0.001) ( Figures 5B, D) .
255
Depletion of Stmn2 significantly reduced the extent of colocalization between glucagon and 256 Lamp2A compared to wild type cells (PCC = 0.001, p<0.01) ( Figures 5C, D) . Interestingly, the 257 signal intensity of the endo-lysosomal marker, Lamp2A, was significantly increased (p < 0.01) 258 upon overexpression of Stmn2, but not upon depletion of Stmn2 ( Figure 5E ).
259

Discussion
260
Our overall hypothesis states that glucagon secretion from α cells is mediated by proteins that are 261 associated with glucagon within secretory granules. To this end, we have shown that a neuronal 262 protein, Stmn2, can be localized to the secretory granules of αTC1-6 cells. We validated this 263 association in mouse pancreatic islets, and through silencing and overexpression experiments, we 264 showed that Stmn2 can play a role in glucagon secretion by trafficking through the endosomal-265 lysosomal pathway. 266 We have previously identified Stmn2 as part of a network of proteins that associate with glucagon 267 within the secretory granules of αTC1-6 cells (21). Data in the current study show that Stmn2 is suggests that transcriptional silencing programs may operate in a cell-specific manner.
278
Our results indicate that Stmn2 is localized largely to punctate structures within aTC1-6 cells, 279 notably at the plasma membrane. Its colocalization with glucagon, ChGA and VAMP2 at the 280 plasma membrane suggests that it is efficiently sorted from the Golgi to plasma membrane- these Cys residues is required for localization in secretory granules in aTC1-6 cells, it is likely that 289 this is a conserved sorting mechanism in neuroendocrine cells.
290
Consistent with its localization within secretory granules, Stmn2 is co-secreted with glucagon in 291 response to K+. While Stmn2 is a membrane-bound protein, it is also present in normal human 292 blood as determined by plasma proteomics (37) and therefore can be also secreted. There is some 293 evidence of a lower molecular weight form of Stmn2 that may correspond to a cleaved, soluble 294 form (36) (38). In our model, it may be that a portion of Stmn2 becomes cleaved within the 295 secretory granule, thus becoming part of the soluble cargo that is released.
By manipulating the expression of Stmn2, we were able to demonstrate a role in the control of 297 glucagon secretion. There is precedence for a role for Stmn2 in the regulation of neuroendocrine 298 secretion that has some interesting parallels with our results. While we showed that silencing of 299 Stmn2 increased the constitutive secretion of glucagon, one study showed that silencing Stmn2 in 300 PC12 cells decreased both basal and stimulated secretion of chromogranin A (23 
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A further clue to the mechanism of Stmn2 in the regulation of glucagon secretion was provided by 309 overexpression experiments, in which we showed an almost complete shutdown of glucagon 310 secretion and an increase in the localization of glucagon in early endosomes and lysosomes. These 311 results suggest a mechanism whereby an increase in Stmn2 in the alpha cell inhibits glucagon 312 secretion by targeting glucagon secretory granules for degradation in the endosome-lysosome 313 pathway, perhaps in a manner similar to that of insulin secretory granules in Type 2 diabetes (39).
314
Very recently, it has been shown that insulin secretion can be inhibited by the targeting of 315 proinsulin for lysosomal degradation by Rab7-interacting lysosomal protein (RILP) (40). The
316
proposed mechanism of action was through interactions between RILP and an insulin secretory 317 granule membrane protein, Rab26. It is tempting to speculate that Stmn2 could have a similar 318 mechanism of action in alpha cells. The increase in LAMP2 fluorescence intensity upon Stmn2 overexpression further suggests a role for Stmn2 in modulating glucagon secretion through 320 increased lysosome function or biogenesis. We are currently investigating this mechanism of 321 control of glucagon secretion in mouse islets.
322
In conclusion, we propose that Stmn2, a protein that is associated with glucagon in secretory 323 granules, modulates glucagon secretion in alpha cells by playing a role in its intracellular 
